고려의대 / 이정심, 임채홍*
Abstract
BACKGROUND AND PURPOSE:
Re-irradiation might yield local control (LC) or palliation for locoregionally recurrent rectal cancer (LRRC), but iatrogenic complications are a possible hindrance. We aimed to evaluate the efficacy of re-irradiation to determine optimal treatment of LRRC.
METHODS:
We performed a systematic review of PubMed, MEDLINE, Cochrane Library, and Embase.
RESULTS:
A total of 17 studies involving 744 patients with LRRC were included; median OS ranging from 10 to 45 months (median: 24.5 months). Pooled 1-, 2-, and 3-year OS rates for all patients were 76.1%, 49.1%, and 38.3%, respectively. For patients who underwent re-irradiation and surgery (OP group), these pooled rates were 85.9%, 71.8%, and 51.7%, respectively. For patients who underwent re-irradiation but not surgery (non-OP group), pooled 1-, 2-, and 3-year OS rates were 63.5%, 34.2%, and 23.8%, respectively. The OS difference between both groups was significant for all 3 years (P < 0.05). Pooled 1-, 2-, and 3-year LC rates for the OP group were 84.4%, 63.8%, and 46.9%, and for the non-OP group were 72.0%, 54.8%, and 44.6%, respectively, without significant differences. Pooled grade ≥3 acute and late complication rates were 11.7% and 25.5% in the OP and non-OP groups, respectively. Patients who underwent surgery had a higher risk of grade ≥3 late complications (odds ratio: 6.39). Pooled symptomatic palliation rate was 75.2%.
CONCLUSIONS:
Re-irradiation with or without surgery for LRRC showed oncologic and palliative efficacy. Salvage treatment including re-irradiation and surgery showed higher survival, but the late complication was significantly increased with concomitant surgery.
Author information
Lee J1, Kim CY2, Koom WS3, Rim CH4.
1
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea.
2
Department of Radiation Oncology, Anam Hospital, Korea University Medical College, Seoul, Republic of Korea.
3
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
4
Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Ansan, Republic of Korea. Electronic address: crusion3@naver.com.